ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback